We are excited to finally turn the page on 2020 and get started on 2021 and are looking forward to continuing to provide our Clients with access to best-in-class services and cutting-edge technologies for use in their drug discovery and development programs.
Amid the pandemic, Visikol continued to support its Client’s discovery programs and in parallel worked to develop several new technologies and service offerings. In 2020, Visikol introduced highly multiplexed slide imaging services as well as precision cut tissue slice assays and several new in vitro assays such as immune cell synapse screening and blood brain barrier assays. In 2021, we will be launching several new technologies and services over the next few months which we are very excited about. Please check back in over the next few months to get details on the following:
Coming in 2021
- Light Sheet Imaging Services – We will be launching comprehensive whole tissue clearing, labeling and light sheet imaging services for large intact tissues such as whole rodent brains. This service will be targeted at large intact tissues that have been labeled with fluorescent proteins and will allow Visikol to provide its Clients with a full spectrum of 3D tissue imaging services from high resolution/small volume confocal imaging to lower resolution/large volume light sheet imaging.
- 3D Cell Culture DILI Services – While we currently provide our Clients with NASH and NAFLD services for use in their discovery programs, we seldom leverage these same 3D cell culture models for use in routine DILI studies. Starting in late Q1 of this year, we will be launching well-validated and robust DILI 3D cell culture assays that are affordable and have been tested with over a hundred compounds to date. We will be offering a wide range of endpoints from simple ATP based assays all the way to multiplex high content confocal imaging.
If you have any questions or would like to learn more about our services do not hesitate to reach out to our team.
